This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
We have recently reported that chronic kidneydisease (CKD) is associated with higher likelihood of sudden cardiac arrest (SCA) presenting with non-shockable rhythms (NSR) (pulseless electrical activity/asystole), as opposed to shockable rhythms (ventricular fibrillation/pulseless ventricular tachycardia).
Gene-Based Analysis Predictive analytics is vital in reducing morbidity and mortality, with healthcare startups focusing on early risk prediction and disease detection. Much of heart disease is linked to conditions like diabetes, obesity, or chronic kidneydisease, and specific mutations in nucleic acids help identify them.
Notes: Approved after initial rejection two years prior based on safety data from Japan, where the drug had been used since 2020 It can only be used in kidneydisease patients on dialysis for at least 3 months. Join us as we examine the landmark approvals that are revolutionizing patient outcomes.
BackgroundPatients with heart failure and chronic kidneydisease (CKD) may have an increased risk of death from causes competing with arrhythmic death, which could have implications for the efficacy of implantable cardioverter‐defibrillators (ICDs). Journal of the American Heart Association, Ahead of Print.
With an estimated incidence as high as 22% among these patients, current clinical guidelines recommend using implantable cardioverter defibrillators (ICDs) to help mitigate the risk of SCD.
CASTLE-AF randomized 363 patients with atrial fibrillation and left ventricular ejection fraction of 35% or less, NYHA class II-IV heart failure and having an implanted defibrillator to either catheter ablation or medical therapy with rate or rhythm control [5].
He also had a history of chronic kidneydisease, stage III. Angio had shown some acute disease in the saphenous vein graft to the posterior descending artery off of the RCA. Most recent echo showed EF of 60%. He had recently had a NonSTEMI. He was managed medically with Clopidogrel. However it is classified is not so important!
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content